Product Images Amlodipine And Atorvastatin

This is a medication containing 40mg of amlodipine besylate and 10mg of atorvastatin calcium. It is manufactured by Apotex Corp and comes in a package containing 30 tablets. The recommended storage temperature is between 20°C to 25°C (68°F to 77°F) with moisture protection, and excursions are allowed between 15°C to 30°C (59°F to 86°F). The medication should be dispensed in its original container and the recommended dosage should be followed as described in the package insert.*

Each film-coated tablet contains 40 mg amlodipine besylate and 20 mg atorvastatin calcium. It is recommended to store the medication at controlled room temperature and protect it from moisture. The usual dosage should be consulted in the package insert. The medication is distributed in an original container with 30 tablets. The manufacturer is Apotex Corp. with a location in Toronto, Ontario.*

Each film-coated tablet contains a combination of amlodipine besylate and atorvastatin calcium equivalent to 40mg of amlodipine and 40mg of atorvastatin. The tablets are recommended to be stored within the temperature range of 20°C to 25°C (68°F to 77°F). A temperature range of 15°C to 30°C (59°F to 86°F) is also acceptable. The drug should be protected from moisture and dispensed in its original container. Usual dosage instructions are contained within the package insert. This drug is distributed by Apotex Corp. The dosage strength of each tablet is 10mg/40mg.*

This is a description of a medication called Amlodipine and Atorvastatin Tablets. Each tablet contains 40mg of Amlodipine and 80mg of Atorvastatin calcium. The tablets are stored at 20-25°C (68-77°F) with permitted excursions from 15-30°C (59-86°F). The medication should be protected from moisture and dispensed in its original container. The usual dosage is detailed in the package insert. The tablets are available in a package of 30 and are manufactured by Apotex Corp. The address and contact details of the manufacturer and distributor are given.*

This is a description for Amlodipine and Atorvastatin Tablets, USP that contains 5 mg amlodipine and atorvastatin calcium equivalent to 10 mg atorvastatin. The tablets should be stored between 20°C to 25°C (68°F to 77°F) and should be protected from moisture. The recommended dosage should be seen in the package insert. The tablets are manufactured by Aporax ing, Toronto, Ontario, Canada and distributed by Apotex Corp., Weston, Florida 3336. The product comes in 30 Tablets NDG 60505-3478-3.*

Each film-coated tablet contains 5mg amlodipine besylate and 20mg atorvastatin calcium. The medication should be stored at temperatures between 20°C to 25°C and protected from moisture. The tablets are sold in a container with a usual dosage available in the package insert. This medication is manufactured by Apotex Corp in Ontario, Canada, and distributed in Weston, Florida. No dosage recommendation is available in this text.*

This is a description of a medication containing amlodipine besylate and atorvastatin calcium in a film-coated tablet form. Each tablet contains 5 mg amlodipine besylate equivalent and 40 mg atorvastatin calcium equivalent. It is recommended to store the medication at a temperature range of 20°C to 25°C and protect from moisture. The usual dosage should be consulted as per the package insert. The medication comes in 30 tablets and is manufactured by Apotex Corp.*

This is a description of Amlodipine Besylate and Atorvastatin Calcium tablets, which contain 5mg of Amlodipine and 80mg of Atorvastatin. The tablets should be stored between 20°C and 25°C and protected from moisture. The dosage instructions are as per the package insert. The tablets are manufactured by Apotex Corp in Toronto, Ontario, Canada, and are dispensed in their original container.*

This appears to be the results of a study or experiment involving Amlodipine for a certain period of time (the time is shown in months). The Event Rate, P-value, Hazard Ratio, and 95% Confidence Interval are provided for the treatment group (Amlodipine) in comparison to a control group (Placebo). However, without further context or information it is difficult to provide a more detailed description or interpretation of the data.*

This appears to be data from a study or clinical trial with 1318 patients (618 of them male) evaluating the effects of a drug called Arladipine on vessel disease and stenosis. The study includes information on patients' gender and baseline blood pressure levels. It also provides data related to stent placement and post-treatment measures. However, the text is not clear and contains several errors and misspellings, making it difficult to draw specific conclusions from the information provided.*

This is a tabulated data that compares the placebo vs atorvastatin medication in terms of cumulative hazard (%) over time to the first primary endpoint through four (4) years of follow-up. Atorvastatin showed a hazard ratio of 0.63 (0.48-0.83) with a p-value of 0.001, suggesting a significant difference between the two treatments in preventing the primary endpoint.*

This appears to be a table or figure with incomplete text. It is not possible to generate a useful description without additional context or information.*